Meanwhile, in the last decade, CDK4/CDK6 inhibitors have been developed as novel anticancer agents, especially for hormone receptor-positive/human epidermal growth factor receptor-2 negative (HR-positive/HER2-negative) metastatic and advance breast cancer [13]. The gene discussed is ERBB2; the disease is breast carcinoma.